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Abstract. In human B cells, class II molecules of the 
major histocompatibility complex (MHC-II) accumu- 
late in an endosomal/lysosomal  compartment, the 
MIIC, in which they may encounter and bind peptides. 
An additional molecule required for MHC-II peptide 
binding, HLA-DM (DM), has also been localized to the 
MIIC. Neither the relationship of the MIIC to the en- 
dosomal system nor the mechanisms by which DM lo- 
calizes to the MIIC are understood. To address these is- 
sues, DM localization was analyzed in cells that do or 
do not express MHC-II. DMet[3 heterodimers were lo- 
calized in transfected MHC-II-negative HeLa and 
NRK cells, in the absence of the MHC-II-associated in- 
variant chain, to a prelysosomal/lysosomal  compart- 
ment by immunofluorescence  microscopy. To identify a 
potential targeting determinant, we analyzed the local- 
ization of a chimeric protein, T-T-Mb, in which the cy- 
toplasmic tail of murine DM13 (Mb) was appended to 
the lumenal and transmembrane domains of a cell sur- 
face protein, Tac. Like intact DM, T-T-Mb was local- 
ized to a lysosomal compartment in HeLa and NRK 
cells, as judged by immunofluorescence and immuno- 
electron microscopy. T-T-Mb was rapidly degraded in 
this compartment by a process that was blocked by in- 
hibitors of lysosomal proteolysis. The DMI3 cytoplas- 
mic tail also mediated internalization of anti-Tac anti- 
body from the cell surface and delivery to lysosomes. 
Deletion from the DMI3 cytoplasmic tail of the ty- 
rosine-based motif, YTPL, resulted in cell surface ex- 
pression of T-T-Mb and a loss of both degradation and 
internalization; alanine scanning mutagenesis showed 
that the Y and L residues were critical for these func- 
tions. Similarly, mutation of the same Y residue within 
full-length DMI3 resulted in cell surface expression of 
DMal3 heterodimers. Lastly, T-T-Mb was localized by 
immunoelectron microscopy to the MIIC in a human B 
lymphoblastoid cell line. Our results suggest that a mo- 
tif, YTPL, in the cytoplasmic tail of the 13 chain of DM 
is sufficient for targeting either to lysosomes or to the 
MIIC. 
T|GEN receptors  on the surface  of T  lymphocytes 
recognize  a complex formed between proteins of 
the  major  histocompatibility complex  (MHC)  1 
and peptides derived by intracellular proteolysis of foreign 
or endogenous proteins.  MHC class II antigens (MHC-II) 
are heterodimeric cell surface  glycoproteins  that present, 
to CD4 ÷ T cells, peptides generated predominantly from 
proteins encountered within the endosomal system. The 
pathway by  which  peptides  are  delivered  and  become 
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bound to MHC-II has been the subject of intensive investi- 
gation (22, 26). 
MHC-II a  and 13  chains  assemble  in the endoplasmic 
reticulum (ER) with a third polypeptide known as the in- 
variant (I) chain (18, 39, 42, 51). I chain functions early by 
promoting et13 assembly and ER egress (2, 6, 10, 45, 53, 85) 
and by blocking the peptide binding groove on assembled 
MHC-II molecules  (69, 70, 81). Importantly, I chain also 
functions by directing  MHC-II to the endosomal/lysoso- 
mal system by virtue of a targeting signal in its cytoplasmic 
tail (4, 44, 50, 61). Within endosomal/lysosomal compart- 
ments, I chain is proteolytically  degraded (7, 59). Removal 
of an I chain-derived peptide, CLIP (class II-associated in- 
variant chain peptide), from the MHC-II peptide binding 
cleft allows access of other peptide ligands to the binding 
site (3, 68, 72), including those derived from partially de- 
graded and/or denatured internalized proteins. Ultimately, 
complexes consisting of MHC-II ct13 dimers bound to pep- 
tides are delivered to the cell surface. 
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the  endosomal  compartment(s)  in  which  these  antigen 
processing events occur. Immunoelectron microscopy of 
human B lymphoblastoid cell lines first demonstrated the 
existence of an endosomal/lysosomal compartment in which 
MHC-II  accumulated  (63).  This  compartment,  dubbed 
MIIC (for MHC class II compartment), consists of electron- 
dense structures, characterized by either a multivesicular 
morphology or a multilaminar appearance with extensive 
membrane invaginations (63, 64). The MIIC is accessible 
to internalized proteins, such as soluble horseradish per- 
oxidase, yet it contains only traces of recycling endocytic 
markers, such as the receptors for transferrin or mannose-6- 
phosphate  (63, 64).  In contrast, this compartment is  en- 
riched in lysosomal membrane proteins, such as CD63 and 
lamp-l, and in lysosomal hydrolases, such as cathepsin D 
and acid phosphatase  (63). Additional studies  have also 
implicated organelles with characteristics of lysosomes in 
the generation of MHC-II/peptide complexes (15,  29,  30, 
60, 74), while other studies have implied that formation of 
such complexes and accumulation of MHC-II occur in ear- 
lier endocytic organelles (1, 83,  86)  or in  a  series of se- 
quential  endosomal/lysosomal compartments  (15,  64,  66). 
To understand the mechanisms by which peptides become 
associated with MHC-II, it will be essential to understand 
the position of the MIIC within the endosomal/lysosomal 
system and how components of the MHC-II antigen pro- 
cessing machinery are targeted to this compartment. 
The recent identification of a specific component of the 
antigen-processing machinery, HLA-DM (referred to here 
as DM), offers the opportunity to better understand the 
nature of the MIIC. DM is expressed in cells that also ex- 
press MHC-II and I chain, and consists of two type I trans- 
membrane glycoprotein chains, ct and 13, that are homolo- 
gous to both MHC class I  and class II molecules (16, 17, 
41). Defects in either or both of the genes that encode the 
DMet or 13 chains were shown to underlie the deficiency in 
MHC-II restricted antigen processing functions of mutant 
B  lymphoblastoid and T/B hybrid cell lines  (23, 24,  56), 
and DM expression reconstituted formation of MHC-II/ 
peptide  complexes in  transfected HeLa cells  expressing 
MHC-II and I chain (40). These data suggested that DM 
plays an essential supporting role in antigen processing 
by other MHC-II  antigens.  Indeed, it has recently been 
shown that DM facilitates the release of I  chain derived 
CLIP  and  the  subsequent  binding  of other  peptides  to 
MHC-II (22a, 79a, 79b). A better understanding of the lo- 
calization, trafficking, and biochemical interactions of DM 
will provide insight into the mechanism and subceUular lo- 
calization of the ultimate steps of DM-dependent MHC- 
II/peptide loading. 
DM has been localized in human B lymphoblastoid cells 
and  dendritic cells at steady state  predominantly to the 
MIIC  by  immunoelectron  microscopy  (60,  77).  Unlike 
MHC-II, DM does not appear to associate stoichiometri- 
cally with I chain (23); thus it must localize to the MIIC by 
virtue of a targeting signal other than that in the I chain cy- 
toplasmic tail. We have analyzed the targeting properties 
and steady state localization of DM in non-MHC-II--express- 
ing cells, and addressed how these properties relate to lo- 
calization  in  MHC-II-expressing  "professional"  antigen 
presenting cells. We show that intact DM dimers are tar- 
geted to lysosomes in a variety of nonlymphoid MHC-II- 
negative  cells. Furthermore, by using  chimeric proteins, 
we  show  that  the  cytoplasmic tail  of the  murine  DM13 
chain  is  sufficient  for  targeting  a  heterologous  protein 
both to lysosomes in nonlymphoid cells and to the MIIC in 
B lymphoblastoid cells. The tyrosine-based motif, YTPL, 
present in the DM[3 cytoplasmic tail, is an essential part of 
the lysosomal targeting determinant, and also mediates in- 
ternalization from the cell surface. This determinant is un- 
usual among tyrosine-based lysosomal targeting signals in 
that it is neither preceded by a glycine nor is it present at 
the COOH terminus. Our findings suggest that protein lo- 
calization to the MIIC and to lysosomes may be mediated 
by similar cytoplasmic targeting events. 
Materials and Methods 
Cell Lines and Stable Transfections 
NRK and HeLa cells were maintained as monolayers in DMEM supple- 
mented with 7% (vol/vol) FBS, 50 i~g/ml gentamicin, 100 U/ml penicillin, 
and 100 p~g/ml streptomycin (complete medium). The B-lymphoblastoid 
cell line 721.45,  generously provided by Dr. R. DeMars (University of 
Wisconsin, Madison, WI), was maintained in RPMI 1640 medium supple- 
mented with 15 % fetal bovine serum and the antibiotics mentioned above. 
Stably transfected clones of NRK  and  HeLa  cells expressing selected 
transgenes were generated in order to (a) avoid overexpression in tran- 
siently transfected HeLa  cells of proteins containing targeting signals, 
which resulted in accumulation at the cell surface and reduced rates of 
degradation and internalization, and (b) increase the fraction of NRK 
cells expressing the transgene of interest, because transfection efficiency 
was too low to analyze biochemically. To generate stable transfectants, 
cells were plated sparsely in 10-cm dishes containing 10 ml of complete 
medium. 10-20 Ixg of the plasmid of interest (in some cases linearized) 
was combined with I isg of pSV2Neo (80) or RSVNeo (27), expressing the 
Tn5 aminoglycoside 3' phosphotransferase II gene conferring resistance 
to G418, and used to transfect ceils by the calcium phosphate precipitation 
method as described in  reference 76.  Selection with G418  (Geneticin, 
Gibco/BRL, Gaithersburg, MD; 1 mg/ml for HeLa, 500 ixg/ml for NRK) 
was initiated 2 d after transfection. G418-resistant colonies were expanded 
and assayed for expression by immunofluoreseence microscopy in the ab- 
sence and/or presence of 1 mg/ml leupeptin. Positive lines were main- 
tained in medium containing G418 (500  Ixg/ml for HeLa; 250  p.g/ml for 
NRK). For generation of stably transfected 721.45 cells, 25 Ixg of the plas- 
mid of interest was combined with 1 Ixg of RSV.5 (hygro) (49) and used to 
transfect 107 cells by electroporation, using a Gene Pulser set at 960 txF 
and 240  V  (Biorad  Labs., Hercules,  CA).  Cells were plated at  2,000- 
10,000 viable cells/well in 96-well plates, and selection with hygromycin 
(300  U/ml)  was  initiated  2  d  after  transfection.  Hygromycin-resistant 
clones were assayed for expression by immunofluorescence microscopy 
on poly-L-lysine-coated coverslips as described (52) using cells treated or 
untreated with 50 mM NH4C1. Stable lines were maintained in medium 
containing 200 U/ml hygromycin. 
Plasmids 
All constructs were prepared in pCDM8.1 (8), a modification of pCDM8 
(79),  except  DMct  and  DMI3 constructs.  DMct-  and  DMI3-encoding 
cDNAs were the gift of J. Trowsdale (Imperial Cancer Research Fund, 
London, UK), and were cloned into the XhoI site of pCDM8 by standard 
techniques (76). The plasmids pCDM8-Tac (75) and pCDM8-T-T-G (con- 
taining  Tac  lumenal  and  transmembrane  domains  appended  to  the 
TGN38  cytoplasmic tail; reference 35)  have been previously described. 
T-T-Mb  and  deletion constructs were prepared by the two-step poly- 
merase chain reaction (PCR) procedure (32). Briefly, H-2Mb cytoplasmic 
tail sequences were amplified from RNA prepared from murine spleen 
(the generous gift of Dr. L. King; NCI, Bethesda, MD) by reverse tran- 
scription followed by PCR  (Perkin Elmer, Norwalk, CT)  using a  back 
primer complementary to the end of the coding sequence and a primer in- 
corporating sequences in both the beginning of the coding sequence for 
the Mb cytoplasmic tail and the end of the Tac transmembrane region 
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from T-T-G using a back primer complementary to the previous forward 
primer, the PCR products were mixed and reamplified to generate Tac 
transmembrane/Mb cytoplasmic coding sequences with appropriate Bg111/ 
XbaI restriction sites for replacing the corresponding region in the T-T-G 
plasmid by standard techniques. For deletion constructs, reverse strand 
back primers were made to introduce stop codons after the codons for the 
desired COOH-terminal amino acid. Alanine scanning mutants were gen- 
erated by double PCR using the parent TTM.GSTYA  as template and 
primers introducing point mutants encoding alanine replacements at the 
appropriate amino acid. The DMB.Y248A mutant was prepared in a simi- 
lar fashion using the parent DMI3 cDNA construct, pCDM8-derived plas- 
mids containing HLA-DRA, HLA-DRBI*0101 (48),  and human f chain 
p33 (70) cDNAs have been described. 
Antibodies 
The anti-Tac monoclonal antibody 7G7.B6 (American Type, Culture Col- 
lection, Rockville, MD), anti-Tac polyclonal rabbit serum R3134 (gift of 
Dr, W. Leonard, NHLB1, Bethesda, MD), "anti-Tac" monoclonal anti- 
body (84), anti-DRI3 monoclonal antibody XD5.All (reference 67; gift of 
Dr. E. Long, NIAID, Rockville, MD), anti-human I chain antiserum Ma- 
tilda (52), anti-DRu chain antiserum (reference 58; gift of Dr. H. Ploegh, 
Massachussetts Institute  of Technology,  Cambridge, MA)  anti-lamp-1 
polyclonal rabbit serum (reference 14; gift of Dr. M. Fukuda,  La Jolla 
Cancer Research Foundation, La Jolla, CA), anti-lgpl20 monoclonal anti- 
body LylC6 (reference 47; gift of Dr. I. Mellman, Yale University, New 
Haven, CT), anti-human transferrin receptor monoclonal antibody B3/25 
(Boerhinger Mannheim, Indianapolis, 1N), anti-cation-independent man- 
nose-6-phosphate receptor polyclonal rabbit  antiserum  (gift  of Dr.  B. 
Hoflack, EMBL,  Heidelberg, Germany), anti-TGN38  polyclonal rabbit 
antiserum JH4 (12), and anti-human CD63 monoclonal antibody (AMAC 
Inc., Westbrook, ME) have been described. Anti-human DM antiserum 
was a gift of Drs. H. Zweerink (Merck, Sharp & Dohme, Rahway, NJ) and 
P. Cresswell (Yale University, New Haven, CT). An antibody recognizing 
the cytoplasmic tail of the HLA-DMI3 chain was generated by immuniza- 
tion of a rabbit with a multiple antigenic peptide (MAP) corresponding in 
sequence to amino acids 228 to 241 of DMI3, as described (41). The result- 
ing antiserum was affinity purified by adsorption to the MAP-DMI3 pep- 
tide immobilized on Affigel 15 agarose (Biorad), extensive washing with 
10 mM Tris, pH 7.5, followed by a brief wash in the same buffer contain- 
ing 0.5 M NaC1, elution with 0.1 M glycine pH 2.8, neutralization with 
0.1  M Tris, pH 8, and dialysis against phosphate buffered saline (PBS). 
The affinity purified antiserum (5 v.g/ml) reacted specifically with DMI3 
chains, as judged by immunofluorescent staining of transiently transfected 
HeLa and NRK cells. Staining was competed by addition of the immuniz- 
ing peptide, and no staining was observed in untransfected cells. The anti- 
DM[3 serum had no reactivity towards the murine H-2Mb chain, as judged 
by immunofluorescence microscopy on transient and stable T-T-Mb trans- 
fectants. Fluorescein isothiocyanate-(FITC) and lissamine rhodamine sul- 
fonyl chloride- (LRSC) conjugated antibodies specific for mouse or rabbit 
immunoglobulins (Ig), used as secondary antibodies in immunofluores- 
cence experiments, were obtained from Jackson ImmunoResearch (West 
Grove,  PA).  Phycoerythrin-conjugated anti-Tac  (anti-CD25)  antibody 
was obtained from AMAC. 
Immunofluorescence Microscopy 
Cells were plated sparsely on sterile coverslips in 6-well dishes. For tran- 
sient transfections, cells were transfected the next day using the calcium 
phosphate precipitation method (76) and 3-5 ~g of plasmid DNA, except 
where indicated. For cotransfection of DRct, DR[3, I chain, and T-T-Mb 
expressing cDNAs, 1 i~g each of DRct and DRI3, 3 txg of T-T-Mb, and 5 txg 
of I chain plasmids were used. Medium was replaced the following day. 
Cells were subjected to fixation with 2% formaldehyde in PBS generally 
36-42 h after transfection. For stably transfected cells, cells grown on cov- 
erslips were similarly fixed when they reached 50-70%  confluence. In 
some cases, cells were pretreated for 4 h with medium containing 1 mg/ml 
leupeptin before fixation. For immunofluorescent internalization assays, 
cells were incubated in sterile 7G7.B6 supernatant supplemented with leu- 
peptin for 4 h before fixation. Coverslips containing fixed cells were pro- 
cessed for indirect immunofluorescence microscopy as described (35), us- 
ing various primary antibodies and fluorochrome-conjugated secondary 
antibodies. Cells were analyzed on a Zeiss photomicroscope using a 63x 
Planapo lens, and photography was with Kodak Tri-X-pan ASA 400 film. 
Cryosectioning and Immunoelectron Microscopy 
Stable transfectants that had been treated for 4 h with 1 mg/ml leupeptin 
(HeLa and NRK cells) or a combination of I mg/ml leupeptin, 0.1 mg/ml 
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane  (E-64),  and  0.1 
mg/ml pepstatin A (721.45 cells) were fixed by adding an equal volume of 
fixative (4%[wt/vol] paraformaldehyde/0.4% [wt/vol] glutaraldehyde/0.1 M 
sodium phosphate, pH 7.4) to cells in tissue culture medium and incubat- 
ing for 2 h at room temperature. Cells were rinsed in PBS containing 0.15 M 
glycine and embedded in 10%  (wt/vol) gelatin. Gelatin blocks were in- 
fused with 2.3 M sucrose for 16 h at 4°C, and then frozen in liquid nitro- 
gen. Thin cryosections (50  nm) were made with a  cryo-ultramicrotome 
(Reichert Ultracut S) and Drukker Knives. For single labeling, sections 
were sequentially incubated at room temperature with polyclonal anti- 
body to Tac and protein A conjugated to 10-nm gold particles. For double 
labeling, sections were stained first with antibody to Tac and protein A 
conjugated gold, followed by the indicated second antibody and protein A 
conjugated gold of a  different size, as described (63).  For quantitation, 
sections from at least 20 cells were analyzed for each cell type. 
Flow Cytometry 
For assaying cell surface expression of DM heterodimers containing either 
intact DM[3 or DMI3 with a  cytoplasmic tail mutation, HeLa cells were 
transiently transfected with 2 Ixg each of pCDM8 plasmids encoding DMI~ 
or DMB.Y248A, DMet, and Tac as a control, along with 4 ~g of pCDM8.1 
vector without an insert. After 36--40 h, a sample of cells was analyzed by 
immunofluorescence microscopy to determine transfection efficiency, and 
the remaining cells were released from culture dishes with 10 mM EDTA/ 
PBS, counted, and washed. A  fraction of the cells was pulse-labeled for 
quantitation of expressed DMal3 heterodimers by immunoprecipitation 
with anti-DM antiserum, SDS-PAGE analysis, and Phosphorlmager anal- 
ysis (see below). The remaining cells were bound to phycoerythrin-conju- 
gated anti-Tac monoclonal antibody (AMAC, Westbrook, ME) and rab- 
bit anti-DM antiserum followed by FITC-goat anti-rabbit Ig, and surface 
fluorescence was quantitated by flow cytometry on a FACScan (Becton 
Dickinson) using the CyQuest software. The analysis shown was gated for 
cells expressing moderate surface levels of Tac; immunofluorescence anal- 
ysis showed that 95% of these cells coexpressed DM heterodimers. 
Metabolic Labeling 
For metabolic labeling of stable transformants of HeLa or NRK cells, 
0.5-1  ×  10  7 cells were trypsinized from dishes, and then incubated in sus- 
pension in methionine/cysteine-free  DMEM containing 3-5 % dialyzed fe- 
tal bovine serum for 30 min at 37°C. Cells were pelleted and pulse labeled 
by resuspension in the same medium containing 2 mCi/ml Tran35S-label 
(ICN, Costa Mesa, CA) or EXPRE35SS  (New England Nuclear, Boston, 
MA)  for  20  rain  at  37°C.  Cells  were  pelleted  again,  resuspended in 
DMEM supplemented with 15 × excess methionine and cysteine and 10% 
FBS, and chased for various periods of time. Addition of lysosomal inhib- 
itors, as indicated in the text, was at the start of the chase period. Aliquots 
of cells and supernatants were collected at each time point. Cells were 
washed once in ice cold PBS, and cell pellets and supernatants were fro- 
zen on dry ice and stored at -70°C. 
lmmunoprecipitation 
Metabolically labeled cell pellets were thawed and resuspended in ice cold 
lysis buffer (50 mM Tris, pH 7.4/300 mM NaCl/1%[wt/vol] Triton X-100/ 
0.02% [wt/vol] NaN3/20 mM iodoacetamide) with a cocktail of protease in- 
hibitors (0.25 mM 4-[2-aminoethyl]-benzenesulfonyl  fluoride, 0.1 mM Nct- 
p-tosyl-L-lysine-chloromethyl ketone,  0.1  mM  N-tosyl-L-phenylalanine 
chloromethyl ketone, 33  ~g/ml aprotinin,  10  i~g/ml leupeptin, 5  ixg/ml 
E-64, and 5 ixg/ml pepstatin A) and incubated on ice for 20-30 min. Cell 
supernatants from each time point were adjusted to similar buffer condi- 
tions. Nuclei and insoluble debris were pelleted by centrifugation for 10- 
15 min in a microcentrifuge at 4°C. Lysates and supernatants were pre- 
cleared by incubation with 50 ILl of a 50% slurry of protein A-Sepharose 
(Pharmacia, Piscataway, N J) for 2 h at 4°C, and then subjected to immu- 
noprecipitation with  protein  A-Sepharose  beads  coated  with  7G7.B6 
(anti-Tac) antibody for 2 h at 4°C. Sepharose pellets were washed 4x with 
ice cold wash buffer (50 mM Tris, pH 7.4/300 mM NaC1/0.1% [wt/vol] Tri- 
ton X-100/0.02%  NAN3) and once with ice cold PBS. Pellets were eluted 
by boiling with reducing SDS sample buffer and analyzed by SDS-PAGE 
(43) on Gel-Bond (FMC, Rockland, ME) bound gels made with 9% (wt/ 
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gels were treated for fluorography with 1 M salicylate, dried, and exposed 
to  Kodak  XAR-5  film. For quantitation, dried gels were  analyzed by 
PhosphorImaging analysis on  a  Molecular Dynamics  (Sunnyvale, CA) 
system. The  sum of the radioactivity in  all  cell-associated Tac-specific 
bands as well as material shed into the medium was used when calculating 
degradation rates. 
Quantitative Antibody Internalization Assay 
The assay was performed essentially as described (46) using purified anti- 
Tac  monoclonal  antibody.  Briefly,  anti-Tac  was  radioiodinated  using 
chloramine T  (37).  Untransfected and stably transfected HeLa cells ex- 
pressing the constructs of interest were released from culture dishes with 
10 mM EDTA/PBS, washed, and then bound to radioiodinated anti-Tac 
antibody on ice. After extensive washing at 4°C to remove unbound anti- 
body, bound material was internalized for various periods of time at 37°C; 
at each time point, two aliquots were removed and added to ice cold me- 
dium. At the end of the incubation periods, cells were pelleted. One ali- 
quot was resuspended in medium with and one without 1 mg/ml protein- 
use K, and cells were incubated on ice for 30 min. Cells were isolated by 
centrifugation through a cushion of fetal bovine serum, and cell pellets 
were cut from the bottom of frozen centrifuge tubes and counted in a 
Packard "/ counter. Counts were adjusted for cell number, and the ad- 
justed counts obtained using untransfected cells at each time point was 
subtracted from those obtained from experimental samples to give cor- 
rected counts. The final % internalization was then calculated as the cor- 
rected counts obtained with proteinase K treatment divided by those ob- 
tained without treatment at each time point. The results shown represent 
the pooled data from three separate experiments, each performed in du- 
plicate. 
Results 
Localization of DM in Nonlymphoid Cell Lines 
To characterize the compartment of nonlymphoid cells in 
which DM accumulates, two MHC-II-negative cell lines, 
HeLa and  NRK,  were transiently transfected with plas- 
mids encoding human DM a  and 13 chains. The cells were 
then  analyzed  by  indirect  immunofluorescence  micros- 
copy using an affinity purified antibody directed to the cy- 
toplasmic tail of DM13. The resulting staining pattern in 
cells that expressed both DM a  and 13 chains (Fig. 1, left) 
revealed vesicles of various sizes scattered throughout the 
cytoplasm.  The  vesicles  stained  by  antibodies  to  DM13 
nearly completely overlapped with those stained by anti- 
bodies directed to endogenous lysosomal markers such as 
CD63 or lgp120 (Fig. 1, right).  Localization to the vesicular 
compartment was dependent upon assembly of DM13 with 
DMet chains, since expression of DM13 alone resulted in a 
staining  pattern  consistent  with  ER  retention  (data  not 
shown). These data establish that DMot13 dimers are local- 
ized at steady state to a prelysosome/lysosome-like struc- 
ture in NRK and HeLa cells, consistent with previous ob- 
servations  in  MHC-II-negative  cells  (40)  and  with  the 
presence of both DM and lysosomal markers in the MIIC 
of human  B  cell lines  (63, 77).  These data  also  demon- 
strate  that,  unlike  for MHC-II,  targeting of DM  to  this 
Figure 1.  DMal3 dimers colocalize with markers of lysosomal membranes. HeLa (a and b) or NRK (c and d) cells, grown on coverslips, 
were transiently transfected with plasmids encoding both human DMa  and  13 chains. Cells were fixed with formaldehyde 40  h  after 
transfection and processed for immunofluorescence microscopy, using an affinity-purified rabbit antibody to DMI3 (a and c) and mouse 
monoclonal antibodies to endogenous lysosomal proteins CD63 (b) and lgpl20 (d) as primary antibodies, followed by LRSC-anti-rabbit 
Ig and FITC-anti-mouse  Ig.  Identical fields were photographed using filters for both fluorescein and rhodamine.  Arrows in c  and d 
point to examples of vesicles that are stained with both antibodies. Bar, 10 Ixm. 
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chain, consistent with previous results (23), and imply that 
DM contains an autonomous targeting signal for a prely- 
sosomal/lysosomal compartment. 
The Cytoplasmic Tail of Murine DM~ Is Sufficient  for 
Targeting to a Prelysosomal/Lysosomal Compartment 
Tyrosine- and di-leucine-based peptide sequence motifs in 
the  cytoplasmic  tails  of  many  transmembrane  proteins 
serve  as  endosomal and/or lysosomal targeting  determi- 
nants  (78,  82).  While  the  cytoplasmic tail  of the  DMet 
chain is very short and has no recognizable targeting sig- 
nal, the corresponding tail of the 13 chain is considerably 
longer and contains two conserved tyrosines that could po- 
tentially be part of targeting motifs (references 17, 41; see 
Fig. 5, upper panel). To determine whether targeting infor- 
mation was present in the 13 chain cytoplasmic tail, inde- 
pendent of other DM13 or a  chain sequences, a chimeric 
protein was created in which the mouse DM13 (Mb) cyto- 
plasmic tail was appended to the lumenal and transmem- 
brane domains of a prototypical type I cell surface glyco- 
protein, the IL-2 receptor a  chain (Tac; see Fig. 2, upper 
panel). The localization of the  chimeric protein, termed 
T-T-Mb  (for Tac lumenal-Tac transmembrane-Mb  cyto- 
plasmic tail), was compared with that of intact Tac by in- 
direct  immunofluorescence  microscopy  in  stably  trans- 
fected NRK or HeLa cells using antibodies directed to the 
Tac lumenal domain. 
The immunofluorescence pattern obtained upon stain- 
ing NRK cells expressing the T-T-Mb chimera (Fig. 2 a) 
was distinct from that obtained with cells expressing Tac 
(Fig. 2 c). Whereas Tac was distributed mostly at the cell 
surface with very little in internal structures, T-T-Mb was 
present mostly internally in paranuclear structures, with 
sporadic vesicular staining in the cell periphery. Cell sur- 
face staining was apparent in only a fraction (10-20%) of 
transient transformants expressing high levels of T-T-Mb, 
and  was  undetectable  by  immunofluorescence in  stable 
transformants (although low levels of cell surface staining 
could be detected by other assays; see Fig. 10). Similar re- 
sults were obtained in HeLa cells stably expressing T-T- 
Mb and in several fibroblast cell lines (data not shown), 
showing  that  such  localization was  not  unique  to  NRK 
cells. These data suggested that the DM13 cytoplasmic tail 
caused intracellular localization of the Tac molecule. 
It was surprising that the staining pattern obtained with 
T-T-Mb did not show more prominent staining  of cyto- 
plasmic vesicles, as seen for DMct13 dimers. We reasoned 
that if the DM13 tail were to direct the heterologous Tac 
protein to a lysosome-like compartment, the Tac lumenal 
domain might be degraded and would no longer be de- 
tected  by our  antibodies.  This  would  be  in  contrast  to 
DMe43 dimers which, like class II molecules, are expected 
to be more resistant to proteolysis (22). To test whether 
the T-T-Mb chimera was being degraded, we treated the 
transfectants with leupeptin, an inhibitor of a subset of ly- 
sosomal proteases, before fixation and indirect immuno- 
fluorescence analysis with the antibody to Tac. The result- 
ing staining pattern for intact Tac (Fig. 2 d) was virtually 
unchanged,  still  displaying  cell surface  labeling.  In  con- 
trast,  the  staining  pattern  for T-T-Mb now consisted  of 
multiple bright cytoplasmic vesicles (Fig. 2 b), much as had 
been seen for DMa13 transfectants (Fig. 1). Identical stain- 
ing patterns were obtained with HeLa cells stably express- 
ing T-T-Mb (e.g., see Fig. 3) and a variety of transiently 
transfected fibroblasts (data not shown). An identical pat- 
tern was also obtained using a chimera containing the cy- 
toplasmic tail of the  132 form of murine DM13 (data not 
shown), which has a single amino acid change (serine252 
proline; reference 40). These results demonstrate that the 
cytoplasmic tail of DM13 contains a targeting determinant 
for a vesicular compartment that contains leupeptin-sensi- 
tive proteolytic enzymes in nonlymphoid cell lines. 
To further characterize the compartment to which the 
DM13 tail targeted the Tac antigen, double staining by in- 
direct immunofluorescence analysis was used to colocalize 
T-T-Mb with various endogenous and transfected mole- 
cules. As shown in Fig. 3, a and b, T-T-Mb was colocalized 
in  leupeptin-treated stable  HeLa cell  transfectants  with 
transiently expressed human DMet13 heterodimers. Identi- 
cal results were obtained in NRK cells (data not shown). 
This  demonstrates  that  the  cytoplasmic  tail  of  murine 
DMI3 is sufficient to effect localization of DM in nonlym- 
phoid cells. Note that leupeptin treatment was necessary, 
even in cells coexpressing DM, to observe vesicular stain- 
ing of T-T-Mb. 
To  determine  whether  T-T-Mb  was  delivered  to  the 
same compartment as that in which MHC-II molecules ac- 
cumulated, HeLa cells were cotransfected with plasmids 
encoding human class II chains (HLA-DRct and 13), as well 
as invariant (I) chain and T-T-Mb, and then treated with 
leupeptin before indirect immunofluorescence using anti- 
bodies to both DR13 and Tac. The results, corroborated by 
a similar analysis in M1 fibroblasts (not shown), revealed 
nearly complete colocalization of DR13 and T-T-Mb (Fig. 
3, e and f). Thus, T-T-Mb is targeted in nonlymphoid cells 
to a compartment in which class II antigens accumulate, as 
expected for a compartment with similarity to the B  cell 
MIIC. Finally, T-T-Mb showed nearly perfect colocaliza- 
tion  in  stably  transfected,  leupeptin-treated  HeLa  cells 
with an endogenous marker of lysosomes, lamp-1 (Fig. 3, c 
and d); similar results were observed in NRK cells (data 
not shown). In contrast, the immunofluorescence profiles 
of  markers  for  early  endosomes  (transferrin  receptor; 
HeLa  cells),  the  TGN  (TGN38;  NRK  cells),  and  pan- 
endosomes (cation-independent mannose-6-phosphate re- 
ceptor; NRK cells), were quite distinct from that of T-T-Mb 
in  leupeptin-treated  cells  (data  not  shown).  Taken  to- 
gether, these  data suggest that T-T-Mb is  localized to a 
MIIC-like  compartment  in  nonlymphoid cells,  and  that 
this  compartment  corresponds  to  prelysosomes  and/or 
lysosomes. 
Immunoelectron Microscopy Localization of T-T-Mb 
in Stably Transfected HeLa Cells 
The T-T-Mb-accumulating compartment was further char- 
acterized in stably transfected HeLa cells by immunoelec- 
tron microscopy. After cryosectioning, leupeptin-treated 
cells were stained first with an antiserum to Tac followed 
by protein A conjugated to 10-nm gold particles, and then 
with an antiserum to lamp-1 followed by protein A conju- 
gated to 15-nm gold particles. T-T-Mb was found to accu- 
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tail  of DMI3 is sufficient  for 
targeting  to  a  degradative, 
vesicular compartment. (Up- 
per  panel)  Schematic  dia- 
gram  of  Tac/Mb  chimeras. 
Tac-derived  amino  acid  se- 
quences  are  represented  in 
white, and mouse DMI3 (Mb) 
sequences are represented in 
black.  Numbers  represent 
the number of amino acids in 
the  lumenal  (Lure), trans- 
membrane  (TM),  and  cyto- 
plasmic  (Cyt)  domains  of 
each protein; the signal  pep- 
tide is included for the lume- 
nal  domains.  Amino  (H2  N) 
and  carboxyl  (COOH)  ter- 
mini of each construct are in- 
dicated.  (Lower  panel) Im- 
munolocalization of T-T-Mb 
and Tac in NRK cells. NRK 
cells  grown  on  coverslips 
were  transiently  transfected 
with plasmids encoding T-T- 
Mb  (a and b) or Tac (e and 
d).  After 36-40 h, cells were 
left  untreated  (a  and  c)  or 
treated with 1 mg/ml leupep- 
tin  (b  and  d)  for 4  h.  Cells 
were  then  fixed  and  pro- 
cessed  for  immunofluores- 
cence  microscopy  using  a 
monoclonal antibody to Tac 
and  LRSC-anti-mouse  Ig. 
Bar, 10 I~m. 
mulate predominantly in the membranes of dense, multi- 
vesicular structures  characteristic of lysosomes (Fig. 4 a). 
Lamp-1 was also found in these round, nontubular struc- 
tures,  confirming their  identity as lysosomes.  Gold parti- 
cles corresponding to T-T-Mb were found less frequently 
in tubulo-vesicular structures characteristic of the TGN, as 
well as in Golgi and ER structures.  Only rarely was stain- 
ing observed on the cell surface. The data confirm that the 
predominant steady state  distribution  of T-T-Mb is in in- 
ternal structures of HeLa cells, consistent with the conclu- 
sion that the DMI3 tail confers lysosomal targeting. 
Identification of a Targeting Motif in the DMfl 
Cytoplasmic Tail 
A  subset  of tyrosine-based cytoplasmic tail  targeting  de- 
terminants  for  post-Golgi  compartments  consists  of the 
motif YXXQ, in which Y corresponds to tyrosine, X corre- 
sponds to any amino  acid and O  corresponds  to a  bulky 
hydrophobic residue,  such  as leucine,  isoleucine,  phenyl- 
alanine,  or methionine  (82).  Many lysosomal transmem- 
brane  proteins  have  such  a  YXX•  sequence  at  their 
COOH-termini, most often preceded by a small side chain 
residue, such as glycine or alanine. The cytoplasmic tails of 
both  murine  and  human  DMI3  contain  a  YXXQ  motif, 
YTPL, but it resides in the middle of the sequence and is 
preceded by a  series of serine  residues  (see Fig. 5, upper 
panel). To determine if this or other signals was responsi- 
ble  for  targeting  T-T-Mb  to  lysosomes  in  nonlymphoid 
cells, a number of truncations in the tail were constructed, 
and the resulting  immunofluorescence profiles were  ana- 
lyzed in transiently transfected NRK cells, both before and 
after treatment with leupeptin. 
As seen in Fig. 5, a-f, deletion of five residues  (TTM.- 
GSTYA; "GSTYA")  or 10 residues  (TTM.YTPLA;  "YT- 
PLA") from the COOH terminus of the DMI3 cytoplasmic 
tail had no detectable  effects on the immunofiuorescence 
pattern  of T-T-Mb.  In  both  cases,  the  chimera  was  re- 
tained  intracellularly,  and  vesicles  were  observed  upon 
treatment with leupeptin. Localization of TI~M.GSTYA to 
lamp-l-positive lysosomes was confirmed by immunoelec- 
tron  microscopy (Fig.  4  b).  Both  of these  constructs  re- 
The Journal of Cell Biology, Volume 131, 1995  356 Figure 3.  Molecules that colocalize with T-T-Mb in HeLa cells. (a-d) HeLa cells stably transfected with T-T-Mb and grown on cover- 
slips were either untreated (c and d) or transiently transfected with plasmids encoding human DMot and DMI3 chains (a and b). After 
36 h, cells were treated with 1 mg/ml leupeptin for 4 h, and then fixed and processed for immunofluorescence microscopy. (e and f) 
HeLa cells grown on coverslips were transiently transfected with plasmids encoding T-T-Mb, human MHC-II chains DRa and DRI3, 
and I chain before treatment with leupeptin, fixation,  and processing as above. Cells were costained with anti-Tac antibodies (a, c, and e) 
and antibodies to either the transfected DMI3 chain (b), the endogenous late endosomal/lysosomal transmembrane protein lamp-1  (d), 
or the transfected DRI3 chain (f), followed by appropriate FITC- and LRSC-conjugated secondary antibodies. Bars: (a and b) 5 p~m; 
(c-y3 10 txm. 
tained the YTPL motif; it was present at the COOH termi- 
nus  of  the  TI"M.YTPLA  construct.  Removal  of  YTPL 
(TTM.HSSSA;  "HSSSA")  resulted  in  a  complete  loss  of 
the vesicular staining pattern (Fig. 5, g  and h). Like intact 
Tac,  the  TTM.HSSSA  chimera  was  expressed  predomi- 
nantly at the cell surface, both in the absence and presence 
of leupeptin.  Immunoelectron microscopy confirmed that 
the TI'M.HSSSA chimera was localized mostly to the cell 
surface (average 387 gold particles per 100 Ixm, compared 
with 8 and 5 gold particles per 100 p~m of cell surface for T-T- 
Mb and TTM.GSTYA, respectively), with significant stain- 
ing in secretory compartments (ER, Golgi, transport vesi- 
cles), but not in lysosomes (Fig. 4 c). These data  demon- 
strate  that  the YTPL motif is  an essential  component of 
the lysosomal targeting signal in the DM~3 cytoplasmic tail. 
To further delineate  those features  of the YTPL motif 
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immunoelectron microscopy.  Stably  transfected 
HeLa cells expressing either T-T-Mb (a), TTM.GS- 
TYA (b; see below), or the TTM.HSSSA  chimera 
(c, see below) were treated for 4 h with 1 mg/ml 
leupeptin before fixation with glutaraldehyde and 
paraformaldehyde. (a and b) Frozen thin sections 
were prepared and stained first with a polyclonal 
rabbit antiserum to Tac followed by protein A-gold 
conjugates (10-nm particles), and then, after refix- 
ation, with an antiserum to  lamp-1  followed by 
protein A-gold conjugates (15-nm particles).  Sam- 
ples  were  analyzed by  immunoelectron micros- 
copy. Dense lysosomal structures are labeled with 
gold particles of both sizes. The nucleus (n) and 
Golgi apparatus (g)  of the cells shown are indi- 
cated. Bars, 500 nm. (c) Frozen thin sections were 
stained with a polyclonal rabbit antiserum to Tac 
followed  by  protein  A-gold  conjugates  (10-nm 
particles), and then analyzed by immunoelectron 
microscopy.  The  nucleus (n), ER  (e),  and lyso- 
somes (L) are indicated. Bar, 200 nm. 
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and  around  the  motif were  individually mutated  to  ala- 
nine. Mutagenesis was done in the context of the TTM.GS- 
TYA construct, since  its immunolocalization pattern was 
identical  to that  of the  intact T-T-Mb chimera, and  was 
limited  to those  residues  constituting  and  preceding  the 
YTPL motif; distal residues were deemed uncritical, since 
the  TTM.YTPLA  construct  retained  lysosomal localiza- 
tion.  Mutated  constructs  were  expressed  by  transient 
transfection in NRK cells, and leupeptin-treated cells were 
analyzed by indirect immunofluorescence. As seen in Fig. 
6, substitution of alanine for either the tyrosine or leucine 
residues within the YTPL motif completely ablated lyso- 
somal targeting,  and  resulted  in  a  protein localized  pre- 
dominantly to the plasma membrane (Fig. 6, e and h). In 
contrast,  there were no noticeable effects on localization 
by substitution of alanine for either the threonine or pro- 
line residues (Fig. 6, f and g) or for any of the three serine 
residues preceding the YTPL motif (Fig. 6, b-d). These re- 
sults suggest that the tyrosine and leucine residues are crit- 
ical for lysosomal localization, but that other positions are 
more permissive of alanine substitution. 
Lysosomal Degradation of T-T-Mb 
The morphological data presented above show that T-T- 
Mb accumulates in a lysosomal compartment in the pres- 
ence  of an inhibitor  of lysosomal proteases. To confirm 
that T-T-Mb is targeted to a degradative compartment in 
the  absence  of inhibitors,  trafficking  was  analyzed  bio- 
chemically  by  pulse/chase  analyses.  Stably  transfected 
HeLa cells  expressing  T-T-Mb, TTM.GSTYA  (retaining 
YTPL), TTM.HSSSA (lacking YTPL), or intact Tac were 
metabolically pulse labeled with [35S]methionine/cysteine, 
and then chased for up to 8 h with excess unlabeled me- 
thionine/cysteine.  Lysates  and  supernatants  from  each 
time point were analyzed by immunoprecipitation with an- 
tibodies to Tac and subsequent SDS-PAGE, followed by 
autoradiography and PhosphorImager analysis. As seen in 
Fig. 7 A, both intact Tac and TTM.HSSSA were quite sta- 
ble over the 8 h  of the experiment. In contrast, both the 
T-T-Mb and TTM.GSTYA chimeras rapidly disappeared 
from the cells. The loss could not be attributed to shedding 
of the Tac lumenal domain, as shown by immunoprecipita- 
tion from the cell supernatants  at each time point (Fig. 7 
A), suggesting that the loss was due to intracellular degra- 
dation. The results of pulse/chase analyses for both stably 
transfected HeLa and NRK cells are quantitated in Fig. 7 
B. T-T-Mb had a half-life of ~2.5-3 h in HeLa cells, com- 
pared  with  a  half-life  of  greater  than  8  h  for  Tac  or 
TTM.HSSSA.  Degradation  of  T-T-Mb  was  even  more 
rapid in NRK cells, in which the half-life was only 1-1.5 h. 
These data imply efficient lysosomal delivery of the T-T- 
Mb chimera that is dependent on the YTPL motif. 
To  demonstrate  that  the  degradation  observed  above 
was due to proteolysis in a lysosomal compartment and to 
correlate the morphologic and biochemical results, the ef- 
fect on degradation of various lysosomal inhibitors was an- 
alyzed in a pulse/chase experiment. As seen in Fig. 8 A and 
quantitated  in Fig.  8 B, the nearly complete loss of T-T- 
Mb from lysates of stably transfected HeLa cells observed 
after 8 h of chase was at least partially blocked by all lyso- 
somal inhibitors tested, including leupeptin (Leu), ammo- 
nium chloride (NHaC1), methionine methyl ester (MME), 
and  a  combination of inhibitors  (leupeptin,  pepstatin A, 
E-64,  and  methionine  methyl  ester;  LPEM).  The  data 
firmly establish that T-T-Mb is proteolytically degraded in 
a lysosomal compartment. 
The YTPL Motif Is Necessary  for Lysosomal Delivery 
of DMa[3 Dimers 
The experiments outlined above show that the YTPL mo- 
tif in the DM~ cytoplasmic tail is sufficient to confer lyso- 
somal targeting to a  heterologous protein. To determine 
whether this motif is also necessary for lysosomal target- 
ing of the intact DM complex, the tyrosine residue within 
the YTPL motif in the cytoplasmic tail of the full-length 
DM~3 molecule was mutagenized to alanine  (resulting in 
DMB.Y248A), and the localization of DMetl3 dimers con- 
taining wild-type DMI3 or DMB.Y248A  was analyzed by 
indirect  immunofluorescence  in  HeLa  cells.  The  results 
show  that  while  DM  dimers  containing  wild-type  DMI3 
chains were localized predominantly to lysosomes (Fig. 9 
a), the majority of dimers containing DMB.Y248A  were 
present at the cell surface (Fig. 9 b, although a low level of 
vesicular staining was still visible). Analysis of the trans- 
fectants by flow cytometry (Fig. 9 c) convincingly illustrated 
the effect of the tyrosine mutation on cell surface expres- 
sion  of  DM;  transfectants  expressing  DM  dimers  with 
wild-type DMI3  displayed  only low levels of surface  ex- 
pression at best, whereas those with mutated DMB.Y248A 
exhibited much higher levels of surface expression, com- 
parable to that of a  bona fide cell surface marker, CD4 
(not shown). Thus, the tyrosine within the YTPL motif is 
necessary for efficient lysosomal delivery of the intact DM 
molecule. 
The DMfl Cytoplasmic Tail Acts as an 
Internalization Signal 
Many of the tyrosine-based signals that cause localization 
of proteins to lysosomes also act as internalization signals 
(82). To determine whether the DMI3 cytoplasmic tail also 
contained a signal for internalization from the cell surface, 
antibody uptake experiments were performed. Radioiodi- 
nated antibodies to Tac were bound on ice to the surface 
of HeLa cells  stably  expressing  T-T-Mb, TTM.GSTYA, 
TFM.HSSSA,  or Tac,  and  then  bound  antibody was  al- 
lowed to internalize for various times at 37°C.  Internaliza- 
tion was measured as a function of inaccessibility of cell- 
associated antibody to proteinase K  added to intact cells 
on ice after the 37°C incubation.  As shown in Fig.  10 A, 
while both T-T-Mb and TTM.GSTYA transfected cells ini- 
tially bound much less anti-Tac antibody at the cell surface 
(see figure legend), the bound antibody was rapidly inter- 
nalized. For T-T-Mb, nearly 70% of the antibody initially 
bound at 0°C was internalized by 5 min. The TTM.YTPLA 
chimera  also  mediated  rapid  internalization  (data  not 
shown), consistent with an essential role for the YTPL mo- 
tif. In contrast, Tac and TTM.HSSSA, in which the YTPL 
motif  was  deleted,  internalized  anti-Tac  antibody  at  a 
much slower rate (15-20%  by 20 min). When continuous 
antibody uptake was  analyzed  in  leupeptin-treated  T-T- 
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the cytoplasmic tail of DM[3 
is an essential component of 
the  targeting  determinant. 
T-T-Mb  (a  and  b)  or  T-T- 
Mb-derived  chimeras  with 
progressive  COOH-terminal 
truncations (c and d, TI'M.GS- 
TYA; e  and f, TrM.YTPLA; 
g  and  h, TTM.HSSSA) were 
transiently  transfected  into 
NRK  cells  grown  on  cover- 
slips. Cells were untreated or 
treated with 1 mg/ml leupep- 
tin  as  in  Figs.  2  and  3,  and 
then  processed  for  immuno- 
fluorescence  using  a  mono- 
clonal  antibody  to  Tac  and 
LRSC-conjugated  anti-mouse 
Ig. The constructs are named 
for  the  remaining  COOH- 
terminal sequence  in the cy- 
toplasmic tail as indicated in 
the upper panel; e.g., TTM.GS- 
TYA  (GSTYA)  is  truncated 
after  the  sequence  GSTY, 
etc. Bar, 10 Ixm. 
The Journal of Cell Biology, Volume 131, 1995  360 Figure 6.  The Y and L residues are the most critical components of the DMI3 targeting determinant. As indicated in the top panel, point 
mutations were separately introduced into codons #245-251  (relative to full-length H-2Mb) of the Mb sequence in the TTM.GSTY~ 
chimera, converting each codon individually into an alanine codon. Plasmids encoding individual alanine scanning mutants were tran- 
siently transfected into NRK cells, and leupeptin-treated cells were processed for immunofluorescence microscopy as described in the 
previous figures using a monoclonal antibody to Tac and LRSC-conjugated anti-mouse Ig. Each mutant is named for the codon that is 
mutated to alanine; e.g., $245A (b) has serine #245 converted to alanine, a (-) shows the immunofluorescence profile with nonmutated 
TTM.GSTY~. Bar, 10 ixm. 
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sis  of  T-T-Mb  degradation. 
(A) Stably transfected HeLa 
cells  expressing  T-T-Mb 
(lanes  1-9),  TFM.GSTYA 
(lanes  10-18), TrM.HSSSA 
(lanes 19-27; see Fig. 5, top 
panel for description) or Tac 
(lanes 28-36) were metaboli- 
cally  labeled  with  Tran35S  - 
label  for  20  min,  and  then 
chased  for  the  indicated 
times in the presence of ex- 
cess  unlabeled  methionine 
and  cysteine.  Cells  and  su- 
pernatants were collected at 
each  time  point,  and  both 
cell lysates and supernatants 
(Supe) were  immunoprecip- 
itated  with  a  monoclonal 
antibody  to  Tac.  Immuno- 
precipitates  were  analyzed 
by SDS-PAGE and fluorog- 
raphy.  The  positions of the 
unprocessed glycosylated ER 
precursor of Tac (P) and the 
fully processed, mature form 
(M)  are indicated.  (B)  Gels 
in  A  and  gels  of  similar 
pulse/chase  experiments  us- 
ing  stably  transfected  NRK 
cells  expressing  T-T-Mb, 
TTM.GSTYA, TI~M.HSSSA, 
or  Tac  were  analyzed  by 
PhosphorImaging  analysis, 
and  bands  corresponding to 
Tac  or the  various Tac  chi- 
meric proteins were  quanti- 
tated  at  each  time  point. 
Quantitation  represents  the 
sum of relative intensities of 
all specific bands in precipi- 
tates  from  both  lysates and 
supernatants  at  each  time 
point, divided by the sum of 
all specific bands  in  the  ly- 
sates after the pulse. It should 
be noted that in NRK cells, a large fraction of both TTM.HSSSA and Tac was shed into the medium at later time points (up to 75% of 
starting material by 4 h of chase; data not shown). A smaller but still significant fraction of these molecules was shed by HeLa cells (ob- 
servable in longer exposures of the gels). Very little of the T-T-Mb or qTM.GSTYA molecules were shed by either cell line. 
Mb-expressing cells by immunofluorescence  microscopy 
(Fig.  10  B),  the  internalized  antibody  colocalized  with 
both  the  endogenous  lysosomal  marker,  lamp-1  (HeLa 
cells)  and  the  total  pool  of  synthesized  T-T-Mb  (not 
shown). In contrast, untransfected cells or cells expressing 
TTM.HSSSA  showed  no  uptake  by this  assay  (data  not 
shown).  This  suggests that  those  T-T-Mb molecules that 
appeared transiently on the cell surface and that were in- 
ternalized were targeted to lysosomes. 
The DMfl Tail Mediates Localization of Tac to the 
MIIC in Human EBV-transformed B Cells 
The  previous experiments demonstrate  that  both DMal3 
dimers and a chimeric protein containing the murine DM[3 
cytoplasmic tail are targeted to a  lysosomal compartment 
in nonlymphoid MHC-II-negative cells. To address whether 
the DM~ cytoplasmic tail YTPL motif alone was sufficient 
for targeting to the MIIC in antigen-presenting cells, T-T-Mb 
and TTM.HSSSA  were localized by immunoelectron  mi- 
croscopy in stable transfectants of a human B lymphoblas- 
toid cell line, 721.45.  As seen in Fig. 11 a, T-T-Mb was lo- 
calized in this cell line predominantly to internal structures 
with  a  dense,  multivesicular and  multilaminar  morphol- 
ogy. As in HeLa cells, only very little T-T-Mb staining was 
observed at the cell surface. In contrast, TTM.HSSSA was 
localized almost exclusively to  the  cell surface  (240  gold 
particles per 100  ~,m, compared with 8  gold particles per 
100  Ixm for T-T-Mb),  with  additional staining evident in 
early secretory structures  (Fig. 11  b). Only very few gold 
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endocytic structures.  These data indicate  that  the YTPL 
motif in the DM[3 cytoplasmic tail confers localization to 
an endosomal/lysosomal structure in a "professional" anti- 
gen-presenting cell, such as a B-lymphoblastoid cell line. 
To  determine  whether  T-T-Mb  was  localized  to  the 
MIIC  in  these  cells,  cryosections  were  immunolabeled 
with antibodies to Tac and to either MHC-II or the lysoso- 
mal/MIIC marker lamp-1. As  seen in Fig.  12 a, T-T-Mb 
could be colocalized with lamp-1 in dense, multivesicular 
structures in these cells, much as had been seen in HeLa 
cells.  T-T-Mb and  CD63  were  also  colocalized  in  these 
structures  (data  not  shown).  Those  multivesicular  and 
multilaminar structures that contained MHC-II molecules 
were also stained with antibodies to T-T-Mb (Fig.  12 b). 
This demonstrates that the DM[3 cytoplasmic tail can con- 
fer  localization  to  the  MIIC.  Interestingly,  there  were 
some, albeit few, lysosomal structures that contained T-T- 
Mb but did not contain MHC-II molecules (see Fig. 12 b). 
Similar  localization  to  both  lysosomes and  MHC-II-rich 
structures has been seen for lamp-1 and for CD63 (63, 64). 
Thus, while the targeting signal in the cytoplasmic tail of 
DM[3 is sufficient to confer localization to the MIIC, some 
other region of DM[3 or the DMa[3 dimer may be neces- 
sary for exclusive partitioning from classical lysosomes. 
Figure 8.  The degradation of T-T-Mb during the chase occurs in 
lysosomal compartments. HeLa cells stably transfected with T-T- 
Mb were metabolically labeled for 20 min (0 chase; lane 1) as in 
Fig. 7, and then chased for 8 h in the absence (-; lane 2) or pres- 
ence of the following inhibitors of lysosomal proteolysis, traffick- 
ing, or function:  1 mg/ml leupeptin (Leu; lane 3); 50 mM NH4C1 
(NH4C1; lane 4); 20 mM methionine methyl ester (MME; lane 5); 
and a combination of 100 ~g/ml each of leupeptin, pepstatin A, 
and E-64 with 20 mM MME (LPEM;  lane 6). Cell lysates from 
each time point were immunoprecipitated with a monoclonal an- 
tibody  to  Tac,  and  immunoprecipitates  were  fractionated  by 
SDS-PAGE. Gels were analyzed  by (A) fluorography and (B) 
Phosphorlmaging analysis and band quantitation.  Arrows in A 
point to the ER precursor form of T-T-Mb (P) and the processed, 
mature form (M), and arrowheads point to probable cleavage in- 
termediates of T-T-Mb that remain intact after inhibition of some 
proteolytic events. The quantitation in B is a measure of the sum 
of the intensity of all T-T-Mb-related bands with each treatment 
at each time point divided by the sum of the intensity of all bands 
present at the pulse time point. 
Discussion 
Lysosomal Targeting of DM in Nonlymphoid Cells 
We have shown that assembled DMal3 dimers are local- 
ized at steady state to the same compartment as endoge- 
nous lysosomal proteins, such as CD63 and lgp120, in non- 
lymphoid class II-negative cells.  In multiple experiments 
using transiently transfected HeLa or NRK cells, virtually 
all vesicles containing lysosomal markers contained coex- 
pressed DM molecules (see Fig. 1). The lysosomal target- 
ing of DM in fibroblasts was dependent on assembly of ct 
chains with [3 chains. The immunofluorescent staining pat- 
tern  for DMI3 in transfected cells that did not coexpress 
DMet  chains  suggested  localization  to  the  ER  (data  not 
shown). This demonstrates the requirement for assembly 
of the DMctl3 complex in order to exit the ER, consistent 
with observations for other multi-subunit complexes (36). 
It is worth noting that, unlike for MHC-II molecules, effi- 
cient ER egress (2, 6,  45,  85) and lysosomal targeting (4, 
44,  50)  of DM  were  independent  of expression  of the  I 
chain in all cell types examined. Our results therefore indi- 
cate  that  DM  must  possess  its  own  lysosomal targeting 
signal. 
A  Cytoplasmic Targeting Signal Directs DM 
to Lysosomes 
Using  a  chimeric protein  approach, we have shown that 
the cytoplasmic tail of the murine DMI3 chain (Mb) is suf- 
ficient  to mediate lysosomal targeting  of a  heterologous 
protein in nonlymphoid cells (Figs. 2-4). The localization 
of the T-T-Mb chimera to the same structures  as assem- 
bled DM complexes (Fig. 3) and the cell surface localiza- 
tion of DM dimers lacking the DM[3  cytoplasmic tail tar- 
geting  signal  (Fig.  9)  make  it  unlikely  that  information 
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Figure 9.  The cytoplasmic  tail of DM13 is necessary for efficient  localization  of 
DMal3 dimers. (a and b) HeLa cells grown on coverslips were transiently  trans- 
fected with 0.5 Ixg of plasmids encoding DMct and either wild-type DM[3 (DMB; a) 
or DMB.Y248A  (b). Cells were fixed with formaldehyde 36 h after transfection, 
and then analyzed by indirect immunofluorescence  microscopy using a rabbit an- 
tiserum to purified  DMet~ complexes  and LRSC-anti-rabbit Ig. (c) HeLa cells 
were  transfected  with  plasmids  encoding  Tac,  DMct, and  either  DM13 or 
DMB.Y248A in 10-cm dishes, harvested 36 h after transfection,  and analyzed by 
flow cytometry using the rabbit antiserum to DMctl3 with FITC-anti-rabbit Ig and 
phycoerythrin-conjugated  anti-Tac. The histogram shown represents surface DM 
staining for cells that were gated for expression of moderate surface levels of Tac 
(a range of 10--400 fluorescence  units). The negative control (-) shows DM stain- 
ing for cells transfected with Tac alone. Dot plot profiles showed a linear relation- 
ship at all expression  levels between Tac and DM staining  for cells transfected 
with Tac, DMct, and DMB.Y248A,  as well as for Tac and a control surface-expressed  protein, CD4 (not shown). In the experiment 
shown, an equivalent fraction of Tac-expressing cells coexpressed DModl3 and DMct/B.Y248A dimers (96.5  % and 96.2%, respectively, 
measured by indirect immunofluorescence  of a sample of the transfected cells). Protein expression levels were higher (1.6- and 2.2-fold 
for DMct and 13, respectively)  in cells transfected with wild-type DM13 relative to those transfected with DMB.Y248A  (measured by 
pulse-labeling, immunoprecipitation,  and Phosphorlmaging analysis of a fraction of the transfected cells), ruling out overexpression of 
DMcdB.Y248A as the cause of the increased surface expression. Bar, 20 p,m. 
other than the 13 chain cytoplasmic tail is necessary for tar- 
geting DM molecules in MHC-II-negative cells. Further- 
more, the T-T-Mb chimera colocalized with MHC-II mol- 
ecules expressed with I chain in transfected HeLa (Fig. 3) 
and M1 cells. These data imply that the DM13 cytoplasmic 
tail serves a targeting function for DM complexes similar 
to  that  for which  the  I  chain  cytoplasmic tail  serves for 
MHC-II, and explains the ability of HLA-DM to reach ly- 
sosomal/endosomal structures  in  the  absence  of I  chain 
(40, 77). 
The compartment to which  the  DM13 tail  targeted the 
Tac chimera was identified as lysosomes by the following 
criteria:  (a)  it  colocalized  by  both  immunofluorescence 
and immunoelectron microscopy with endogenous lysoso- 
mal markers (Figs. 3 and 4); (b) it appeared as an electron- 
dense compartment with typical lysosomal morphology by 
immunoelectron microscopy (Fig. 4); (c) it had proteolytic 
activity (Fig. 7); and (d) proteolysis was inhibited by vari- 
ous pharmacological modifiers of lysosomal protease ac- 
tivity or pH (Figs. 2 and 8). Taken together with the colo- 
calization  of T-T-Mb with  transfected  DM~13  dimers  in 
leupeptin-treated cells, these data confirm the notion that 
intact DM molecules are localized to a lysosomal compart- 
ment in nonlymphoid cells by virtue of the cytoplasmic tail 
of the 13 chain. 
Characteristics  of the Lysosomal  Targeting Signal 
in DM 
The critical component of the  DMI~ targeting signal was 
determined from deletion analysis to be a  tyrosine-based 
amino  acid  sequence,  YTPL  (Fig.  5),  that  is  completely 
conserved between human and murine forms of the DM13 
chain  (17,  41).  A  similar  motif is  absent  from all  other 
known MHC class Ia and  class II cytoplasmic tails,  sug- 
gesting that DM may be unique among known MHC mol- 
ecules regarding its  ability to localize to lysosomal com- 
partments in the  absence of I  chain.  On the  other hand, 
similar tyrosine-based YXXO motifs are found in many ly- 
sosomal proteins, such as lamp-1 (GYQTI; reference 25), 
lamp-2 (GYEQF; reference 25),  CD63  (GYEVM;  refer- 
ence 55) and CD68 (AYQAL; reference 33); for lamp-l, 
this sequence has been shown to mediate lysosomal target- 
ing (28, 31, 34, 88). Unlike the majority of these lysosomal 
targeting  signals,  however,  the  YXX~  motif in  DM13 is 
neither located at the COOH terminus of the cytoplasmic 
tail nor preceded by a glycine or alanine, both of which are 
characteristics that have been suggested to be critical for 
lysosomal targeting (31, 34, 88). The YTPL motif also re- 
sembles other tyrosine-based motifs implicated in target- 
ing to endosomes or to the TGN (11, 35, 82, 89). 








,  .~  ,~  ,-..%~  ,-  ,',  .',  ,~  ,t  ,~  ,'.  ................... 
i  i  i 
0  5  10  20 
Time  (rain) 
Figure 10.  The cytoplasmic tail of DMI3 contains an internalization 
signal.  (A) Quantitative  antibody internalization  assay.  Radioiodi- 
nated anti-Tac antibody was bound to the surface of HeLa cells sta- 
bly transfected with T-T-Mb, TFM.GSTYA, TTM.HSSSA, or Tac on 
ice,  and washed cells were then allowed to internalize bound anti- 
body at 37°C for the indicated amount of time. Antibody remaining 
at the cell surface after the 37°C incubation was cleaved by digestion 
with proteinase K on ice, and cell  associated radiolabel before and 
after proteinase digestions was quantitated at each time point. The 
% internalization represents the fraction of total cell associated radio- 
label  at  each  time  point  that  was  proteinase  K-resistant.  The 
amounts of radioactive antibody initially  bound (CPM per 107  cells) 
for  each  transfectant  were  as  follows:  T-T-Mb,  5918  -~  1428; 
TTM.GSTYA, 6540 --_ 369; qTM.HSSSA, 29923 --- 2033; Tac, 15171 
_.+ 861. Note that the amount of bound antibody for the Tac transfec- 
tant should be considered in light of the lower frequency of cells ex- 
pressing the transfected gene relative to cells expressing the chime- 
ras (~50%, relative to ,--,98% for other cells). (B) HeLa cells stably transfected with T-T-Mb and grown on coverslips were exposed to a 
monoclonal antibody to Tac in the presence of 1 mg/ml leupeptin at 37°C for 4 h. Cells were then fixed and processed for immunofluores- 
cence microscopy using LRSC anti-mouse Ig to detect internalized antibody (int. T-T-Mb;  upper  panel) and rabbit anti-lamp-1 antise- 
rum followed by FITC anti-rabbit Ig to detect the endogenous lysosomal marker lamp-1 (Lamp-l; lower  panel). When HeLa cells sta- 
bly transfected with TTM.HSSSA or Tac were similarly incubated with anti-Tac antibody at 37°C, only the cell surface was stained, and 
untransfected cells showed no subsequent staining with LRSC anti-mouse Ig (data not shown). 
The  critical  components  of this  signal  were  shown  by 
alanine  scanning mutagenesis  to be the tyrosine and leu- 
cine (Fig. 6). The tyrosine was also shown to be critical for 
lysosomal  localization  of  intact  DMetl3  dimers  (Fig.  9). 
Surprisingly,  mutagenesis  of  other  residues  within  and 
around the YTPL sequence or deletion of residues COOH- 
terminal  to  the  motif had  no  detectable  effect  on  lyso- 
somal  localization  (Fig.  6).  What  features,  then,  distin- 
guish a lysosomal YXXQ targeting signal from a TGN or 
endosomal signal? The distance of the YXXO signal from 
the membrane (which is similar among DMI3 and other ly- 
sosomal proteins,  such as CD63 [55] and lamp-1  [25], but 
greater in constitutively recycling receptors [82]), the glo- 
bal conformation of the  tyrosine  and leucine  side  chains 
(19, 87), and sequence determinants that are not revealed 
by alanine scanning mutagenesis may all play a role in dis- 
tinguishing  precise  localization  properties  of a  given sig- 
nal.  On the other hand, the YXX~  motifs may be neces- 
sary only for gaining  access to the  sorting  machinery by 
internalization from the cell surface and/or partitioning at 
the level of the TGN; having accessed the sorting machin- 
ery,  additional  determinants  may specify compartmental 
localization. Defining additional elements in the DMI3 tail 
that determine  lysosomal targeting will require  more ex- 
tensive mutagenesis and structural approaches. 
Implications  of Internalization  for the Targeting 
Pathway of T-T-Mb 
The DM~ cytoplasmic tail contained information not only 
for lysosomal targeting in NRK and HeLa cells,  but also 
for internalization from the cell surface (Fig. 10). Internal- 
ization  was  extremely  rapid  in  stably  transfected  HeLa 
cells,  resulting  in  uptake  of 70%  of surface-bound  anti- 
body after 5 min at 37°C. Deletion analysis showed that, as 
with lysosomal targeting, the critical feature for directing 
internalization  was the YTPL motif. Furthermore,  it was 
observed by immunofluorescence microscopy that consti- 
Marks  et al. Cytoplasmic Lysosomal/MllC Targeting Signal in DMfl  365 Figure 11.  Localization of T-T-Mb and TTM.HSSSA in a B-lymphoblastoid cell line by immunoelectron microscopy. Stable transfe~ 
tants of the human B-lymphoblastoid cell line, 721.45, expressing T-T-Mb (a) or TTM.HSSSA (b) were treated for 4 h with 1 mg/ml let 
peptin, and then fixed with glutaraldehyde and paraformaldehyde. Frozen thin sections were stained with anti-Tac antiserum and pr( 
tein A  conjugated to 10-nm gold particles.  Shown are electron micrograph images of representative  cell  samples.  The nucleus (n 
plasma membrane (p), and a mitochondrion (m) of each cell are indicated. Note the staining of dense multilaminar and multivesicul~ 
structures in a and the absence of cell surface staining.  Bar, 500 nm. 
tutively  internalized  antibody  accumulated  in  lysosomal 
structures,  colocalizing with the steady state pool of T-T- 
Mb  (Fig.  10 B).  The  inability  to detect  internalized  anti- 
body in cells expressing  the TFM.HSSSA construct or in 
untransfected  cells  suggests  that  the  antibody  accompa- 
nied internalized  chimeric protein to the lysosomal struc- 
tures. We thus conclude that at least a portion of T-T-Mb 
molecules present in lysosomes are trafficked first throug 
the cell surface. 
The  trafficking  of  a  lysosomally  targeted  transmen 
brane  protein  through  the  cell  surface  is  not  unprec~ 
dented. Similar indirect modes of delivery to late secretoi 
compartments  have been suggested and/or demonstrate 
for a number of lysosomal proteins  (13, 54, 57) as well 
The Journal of Cell Biology, Volume 131,  1995  366 Figure 12.  Presence  of T-T-Mb in the  MIIC and  lysosomes of 
B-lymphoblastoid cells. A stable transfectant  of 721.45 cells ex- 
pressing T-T-Mb was treated for 4 h with 1 mg/ml leupeptin, and 
then fixed and processed for cryosectioning and immunolabeling. 
Cells were labeled first with an antiserum to Tac followed by 10- 
nm gold particle-conjugated  protein A, and then antisera to ei- 
ther lamp-1 (a) or to MHC-II DRa molecules (b) followed by 15- 
nm gold particle-conjugated  protein  A.  A  mitochondrion  (m) 
and the nucleus (n) in the cells are indicated. Note the absence of 
MHC-II staining (15 nm gold) in some of the T-T-Mb-stained 
structures in b. Bar, 200 nm. 
MHC-II/I chain complexes  (5,  15,  71,  73).  If intact  DM 
molecules were  similarly trafficked through the  cell sur- 
face, they might be accessible to a cohort of MHC-II mole- 
cules  and  endocytosed  antigens  present  in  earlier  en- 
docytic compartments, as suggested by others  (1,  15, 21, 
58, 66, 83). This would provide a full complement of anti- 
gen processing molecules throughout the endocytic path- 
way.  On  the  other hand,  evidence  also  exists  for direct 
transport  of lysosomal proteins  (31)  and  MHC-II mole- 
cules (5, 63, 64) from the TGN without prior cell surface 
delivery, suggesting that the indirect pathway may be a re- 
trieval mechanism for missorted proteins.  Accumulation 
of T-T-Mb at the cell surface was clearly exacerbated by 
overexpression in transiently transfected HeLa and COS-1 
cells (data not shown), and some degree of overexpression 
and consequent missorting to the  cell  surface cannot be 
ruled out even in our stable  transfectants.  Lastly, an in- 
triguing  explanation  for  the  observed  internalization  is 
that it may represent a physiological salvage mechanism to 
retrieve DM molecules that had been delivered from the 
MIIC  to  the  cell  surface  together  with  peptide-loaded 
MHC-II molecules. Such a mechanism would allow for the 
recycling of DM molecules for use in  additional  antigen 
processing events, whereas peptide-bound MHC-II mole- 
cules,  now lacking a  strong internalization  signal,  would 
remain at the cell surface. 
The Lysosome as an Alternative Destination for 
MIIC-resident Proteins 
Endogenous DM has been shown to localize in human B 
lymphoblastoid cell lines  and dendritic cells  to the MIIC 
(60, 77).  We have now shown that the cytoplasmic tail of 
DM[3 is sufficient to target Tac to the MIIC when trans- 
fected into the B  cell line, 721.45  (Figs.  11  and  12).  This 
demonstrates that MIIC localization is  mediated by tail- 
associated mechanisms similar  or identical  to those that 
mediate  localization  to  other  endosomal  compartments 
and lysosomes. 
Besides  tyrosine  motifs,  some lysosomal and  internal- 
ized proteins rely on a  second type of targeting determi- 
nant, a di-leucine motif, to effect their localization (20, 38, 
46).  The I  chain contains two modified di-leucine motifs, 
and it is believed that both of these signals are responsible 
for targeting I chain, and hence MHC-II molecules, to the 
MIIC or related compartments (4, 61, 65). Thus, taken to- 
gether with the results shown here, it is likely that target- 
ing to the MIIC, like to other post-Golgi compartments, 
can be mediated by both types of cytoplasmic signal. It re- 
mains to be seen, however, whether the I chain di-leucine 
motifs direct newly synthesized MHC-II to the  identical 
compartment as that to which DM is directed, or to a sepa- 
rate subdomain of the MIIC or subcompartment of the en- 
dosomal system. 
The fact that the DM[3 cytoplasmic tail sequence medi- 
ates localization to lysosomes in nonlymphoid cells and to 
the MIIC in B lymphoid lines suggests that lysosomes may 
serve  as  the  "default"  destination  for DM  and  perhaps 
other proteins in cells that lack a specialized antigen pro- 
cessing compartment.  Delivery of proteins  to  other  cell 
type-specific organelles, such as the cytolytic granules of 
cytotoxic T  lymphocytes and NK cells  (62) and secretory 
granules of rat basophilic leukemia cells (9), may also have 
a component that overlaps with lysosomal delivery. Segre- 
gation of these  organelles  from classical  lysosomes may 
depend upon either cell type-specific targeting and/or fu- 
sion machinery components, or interactions  between  lu- 
menal and/or transmembrane domains of cell type-specific 
cargo molecules. An understanding of the ultrastructural 
localization of DM and T-T-Mb in different cell types and 
the  biochemical  interactions  among MIIC-resident  pro- 
teins will contribute further insights into the biogenesis of 
this late endosomal organelle. 
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